Chronic Limb-Threatening Ischemia Treated With Intravascular Lithotripsy Observational Study (CALCIO)

July 29, 2026 updated by: Cardiovascular and Interventional Radiological Society of Europe
CALCIO is a multicentre, prospective, observational cohort study that will collect real world data on the use of intravascular Lithotripsy (IVL) with the Shockwave IVL system to disrupt calcified femoropopliteal and crural lesions in patients with chronic limb-threatening ischemia (CLTI). The primary objective of CALCIO is to understand the effectiveness of IVL in promoting wound healing and preventing amputation. The secondary objectives of CALCIO are to evaluate the immediate effectiveness of the treatment in restoring vessel patency as well as its safety and impact on patients' quality of life.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Claire Poulet, PhD
  • Phone Number: +41 79 385 16 78
  • Email: calcio@cirse.org

Study Contact Backup

  • Name: Dhwani S. Korde, PhD
  • Phone Number: +4367762942469
  • Email: calcio@cirse.org

Study Locations

  • Austria
      • Eisenstadt, Austria, 7000
        • Krankenhaus der Barmherzigen Brüder
      • Graz, Austria, 8036
        • Medizinische Universität Graz
      • Linz, Austria, 4020
        • Krankenhaus Barmherzige Brüder Linz
      • Vienna, Austria, 1130
        • Klinik Hietzing
      • Vienna, Austria, 1210
        • Klinik Florisdorf
  • Canada
      • Montreal, Canada, H4J 1C5
        • Hôpital Sacré Coeur de Montréal
  • France
      • Dijon, France, 21000
        • CHU François Mitterrand
      • Paris, France, 75014
        • Institute Mutualiste Montsouris
      • Strasbourg, France, 67000
        • Rhéna Clinique de Strasbourg
  • Germany
      • Cologne, Germany, 50937
        • Universitätsklinikum Köln
      • Essen, Germany, 45147
        • Universitätsmedizin Essen
      • Hanover, Germany, 30989
        • KRH Klinikum Robert Koch Gehrden
      • Heilbronn, Germany, 74078
        • SLK-Heilbronn
      • Karlsruhe, Germany, 76133
        • Städtisches Klinikum
      • Mülheim, Germany, 45468
        • Evangelisches Krankenhaus
      • Neumünster, Germany, 24534
        • Friedrich Ebert Krankenhaus
      • Rendsburg, Germany, 24768
        • Schön Klinik Rendsburg
      • Siegen, Germany, 57072
        • St Marien-Krankenhaus
      • Tübingen, Germany, 72076
        • Universitatsklinikum Tubingen
  • Hungary
      • Budapest, Hungary, 1085
        • Semmelweis University
  • Spain
      • Alicante, Spain, 03010
        • Hospital General Universitario Dr. Balmis
      • Granollers, Spain, 08402
        • Hospital General de Granollers
      • Pamplona, Spain, 31006
        • University of Navarra
  • Switzerland
      • Lugano, Switzerland, 6500
        • Ente Ospedaliero Cantonale
      • Winterthur, Switzerland, 8400
        • Kantonsspital Winterthur
  • United Kingdom
      • Bedford, United Kingdom, MK42 9DJ
        • Bedfordshire Hospitals NHS Foundation Trust
      • Frimley, United Kingdom, GU16 7UJ
        • Frimley Health NHS Foundation Trust
      • Hull, United Kingdom, HU3 2JZ
        • Hull University Teaching Hospitals NHS Trust
      • Leeds, United Kingdom, LS1 3EX
        • Leeds Teaching Hospitals NHS Trust
      • Liverpool, United Kingdom, L7 8XP
        • Liverpool University Hospitals NHS Foundation Trust
      • London, United Kingdom, NW3 2QG
        • Royal Free London NHS Foundation Trust
      • London, United Kingdom, NW1 2PG
        • University College London Hospitals Nhs Foundation Trust
      • London, United Kingdom, W2 1NY
        • Imperial College Healthcare NHS Trust
      • London, United Kingdom, SW17 0QT
        • St George's University Hospitals NHS Foundation Trust
      • Manchester, United Kingdom, M13 9WL
        • Manchester University NHS Foundation Trust
      • Newcastle, United Kingdom, NE1 4LP
        • Newcastle upon Tyne Hospitals NHS Foundation Trust
      • Oxford, United Kingdom, OX3 9DU
        • Oxford University Hospitals NHS Foundation Trust
      • Plymouth, United Kingdom, PL6 8DH
        • University Hospitals Plymouth NHS Trust
      • Sheffield, United Kingdom, S10 2JF
        • Sheffield Teaching Hospitals NHS FT

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

CLTI patients with calcified femoropopliteal or crural lesions visible on fluoroscopy and treated with Intravascular Lithotripsy.

Description

Inclusion Criteria:

  • Patient with chronic limb-threatening ischemia (Rutherford Category ≥4)
  • Femoropopliteal and/or crural calcified lesions visible on fluoroscopy;
  • Treatment with IVl using the Shockwave Medical IVL System.

Exclusion Criteria:

  • < 18 years old;
  • Incapacity or refusal to give informed consent;
  • Ongoing pregnancy;
  • Endovascular procedure(s) on the treatment site within 4 weeks before the planned IVL treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Full cohort
Intravascular lithotripsy of femoropopliteal and crural lesions as per standard of care
Device: Shockwave Medical IVL System
Comprehensive system consisting of generator, a connector cable and a single-use sterile catheter with integrated balloon for intravascular lithotripsy of peripheral artery calcification.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Wound healing and freedom from amputation
Time Frame: 12 months
Composite of wound healing defined as the healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening) and freedom from amputation defined as the absence of any amputation of the treated limb: minor (digital, metatarsal), major below the knee or major above the knee (excluding any amputation planned before the IVL procedure).
12 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Wound healing
Time Frame: 24 months
Healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening)
24 months
Freedom from amputation
Time Frame: 24 months
Absence of any amputation of the treated limb: minor (digital, metatarsal), major below the knee or major above the knee (excluding any amputation planned before the IVL procedure).
24 months
Amputation-free survival
Time Frame: through study completion, approximately 2 years
time between IVL treatment and amputation of the target limb, minor (digital, metatarsal), major below the knee or major above the knee (excluding any amputation planned before the IVL procedure)
through study completion, approximately 2 years
Change in Rutherford classification category
Time Frame: 12 and 24 months
Seven classification categories, from 0 (asymptomatic) to 6 (Major tissue loss)
12 and 24 months
Change in foot ischemia
Time Frame: 12 and 24 months
Change in ankle-brachial index or toe pressure, depending on which data is available
12 and 24 months
Change in WIfi score
Time Frame: 12 and 24 months
Three-digit score for comprehensive assessment of wound, ischemia and foot infection
12 and 24 months
CD-TLR-free survival
Time Frame: through study completion, approximately 2 years
time between IVL treatment and any endovascular re-intervention to the target lesion (± 10 mm)
through study completion, approximately 2 years
Primary patency rate
Time Frame: 12 and 24 months
freedom from total occlusion without any endovascular or surgical re-intervention to the target lesion (± 10 mm)
12 and 24 months
Assisted primary patency rate
Time Frame: 12 and 24 months
freedom from total occlusion following additional endovascular or surgical intervention(s) due to restenosis of the target lesion
12 and 24 months
Secondary patency rate
Time Frame: 12 and 24 months
freedom from total occlusion following additional endovascular or surgical intervention(s) due to occlusion of the target lesion
12 and 24 months
Technical success of IVL
Time Frame: on the day of the procedure
residual diameter stenosis ≤30% after IVL and before any potential adjunctive intervention
on the day of the procedure
Overall procedural success
Time Frame: on the day of the procedure
residual stenosis ≤30% by the end of the complete procedure
on the day of the procedure
Patient-reported health-related quality-of-life
Time Frame: at 6, 12 and 24 months
EuroQol questionnaire EQ-5D-5L
at 6, 12 and 24 months
Freedom from clinically-driven target lesion revascularization (CD-TLR)
Time Frame: 12 and 24 months
freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.
12 and 24 months
Frequency and severity of procedural complications and other adverse events
Time Frame: Within 30 days after the procedure
Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe
Within 30 days after the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Cardiovascular and Interventional Radiological Society of Europe

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Shockwave Medical, Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Raman Uberoi, Dr, Oxford University Hospital NHS Foundation Trust, Oxford, United Kingdom
  • Study Chair: Christoph Binkert, Prof. Dr, Cantonal Hospital Winterthur, Winterthur, Switzerland
  • Study Chair: Peter Reimer, Prof. Dr, Municipal Clinic Karlsruhe, Karlsruhe, Germany

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 15, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 15, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 15, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 20, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 29, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 30, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 29, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CALCIO

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings